CompletedNCT03796910Updated Oct 28, 2019

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

A Phase 1 interventional study of SPR720 for SAD and Placebo for SAD in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-28.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 96
Allocation: Randomized
Ages: 18 Years and older
Sex: All

Study summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) following single and multiple ascending dose administration of SPR720 administered orally in healthy volunteers.

Read the detailed description

This is a single-center, phase I, randomized, double-blind, placebo-controlled, first-in-man study. Up to 120 healthy volunteers may be enrolled in this 2-part, multi-cohort study. In both Part 1 and Part 2, sequential cohorts will be exposed to increasing doses of SPR720. Each cohort will enrol 8 subjects, randomized (3:1) to receive SPR720 (6 subjects) or placebo (2 subjects). Each subject will be assigned to only one cohort.

In Part 1 single ascending dose (SAD):

A single oral dose of SPR720 (n=6) or placebo (n=2) will be administered to 8 subjects at an initial dose level of 100 mg. Additional cohorts of 8 subjects will be enrolled to investigate increasing doses of SPR720 ranging from 250 mg to 3000 mg. All subjects will receive SPR720 (or placebo) by oral administration in the fasted state. One Part 1 cohort (the Food Effect Cohort) will receive an additional single dose of SPR720 (or placebo) in the fed state.

Part 2 multiple ascending dose (MAD):

SPR720 (or placebo) will be administered to approximately 3 planned dose cohorts of 8 subjects each. Subjects will receive SPR720 (or placebo) orally once daily for 7 (or 14) consecutive days starting with a planned initial dose of 500 mg. Additional cohorts of 8 subjects will be enrolled to investigate repeated daily doses of SPR720 ranging from 1000 mg to 1500 mg.

For both Part 1 and Part 2, a Safety Monitoring Group (SMG) will review cumulative safety and PK data from each cohort before proceeding to the next cohort/dose level. Doses to be evaluated in each subsequent cohort may be modified by the SMG based on review of safety and PK data from preceding cohorts. Part 2 will run concurrent with Part 1 and will be initiated following SMG review of safety and PK data for the corresponding Part 1 dose level cohort.

Part 1 will be conducted in up to 64 subjects (8 planned dose cohorts of 8 subjects each). Part 2 will be conducted in up to 24 subjects (3 planned dose cohorts of 8 subjects each); additional cohorts of 8 subjects each (up to 16 additional subjects) may be enrolled in either Part if further investigation of SPR720 is required.

Conditions studied

Healthy Volunteers

Keywords

safety
tolerability
pharmacokinetics
SPR720

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: Yes

Eligibility criteria

KEY INCLUSION CRITERIA:

Healthy adult male or female of non-childbearing potential,18 to 55 or ≥ 65 years of age (inclusive) at the time of screening;
Body mass index (BMI) ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive). BMI = body weight (kg) / [height (m)]2 (subjects 18 to 55 years of age); Body mass index (BMI) ≥ 18 and ≤ 32 (kg/m2) and weight between 50.0 and 100.0 kg (inclusive). BMI = body weight (kg) / [height (m)]2 (subjects 65 years of age and older);
Medically healthy without clinically significant (CS) abnormalities as assessed by the Principal Investigator (or deputy) based on the following at screening assessments:
a. Detailed medical history, complete physical examination, vital signs, 12-lead ECG, hematology, blood chemistry and urinalysis laboratory variables;
Willing and able to provide written informed consent;
Willing and able to comply with all study assessments and adhere to the protocol schedule;
If female, must be non-lactating and be of non-childbearing potential;
If male, must agree to not donate sperm for 90 days after the last dose of study drug and, if engaging in vaginal sexual intercourse with a female partner of childbearing potential, agree to use a condom with spermicide in addition to requesting the female partner use a highly effective method of birth control (e.g. intrauterine device, diaphragm with spermicide, hormonal contraceptives) throughout the duration of the study and for 90 days after the last dose of study drug. This criterion also applies to males who have had a vasectomy.

KEY EXCLUSION CRITERIA:

History or presence of any clinically significant disease state in any body system, as assessed by the Principal Investigator (or deputy), that may affect the outcome of the study or compromise the safety of the subject;
Subjects who do not have suitable veins for multiple venipunctures/cannulation as assessed by the Principal Investigator (or deputy) at screening;
Subjects who are unable to demonstrate the ability to swallow a "dummy" capsule (i.e., an empty gelatin capsule) of the size proposed for administration in a particular cohort/dose level;
History of any clinically significant acute illness or surgery within the previous three months;
History of chronic gastritis, gastrointestinal tract disorders, including Clostridium difficile infection; chronic liver or biliary disease;
History of seizure disorder, except for febrile seizures in childhood;
Documented history of significant hypersensitivity reaction or anaphylaxis to any medication;
History of significant allergic disease requiring treatment; allergic rhinitis (hay fever) is allowed unless it has required medication for treatment or prophylaxis within the 14 days prior to randomization;
Clinically significant screening ECG findings as assessed by the investigator;
Subject or family history of cardiac arrhythmia, prolonged QT syndrome, Torsades de pointes, unexplained sudden cardiac arrest or syncope, sick sinus syndrome or other clinically relevant cardiac disease;
Clinically significant abnormalities in vital signs at screening and/or prior to randomization;
Clinically significant screening laboratory abnormalities;
History or suspicion of routine or chronic drug or alcohol abuse or dependence within 1 year prior to randomization, and/or positive urine drug testing at screening or check-in (Day -1);
Reported consumption of alcoholic beverages > 21 units per week on average (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits); positive alcohol urine test at check in (Day -1);
Use of tobacco, nicotine, or nicotine replacement products within 30 days prior to randomization or planned use during the study; positive carbon monoxide breath test at check in (Day -1);
Use of any prescription or non-prescription medication, including herbal products, vitamins and vaccines within 7 days (or 5 half-lives whichever is longer) prior to randomization or planned use during the study period;
Consumption of grapefruit or grapefruit-containing products in the 7 days prior to randomization;
Donation of more than 500 mL of blood or plasma within 30 days prior to randomization, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of study enrolment.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Sequential assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 96 participants (actual)

Study arms

Experimental
SPR720 for SAD
6 out of 8 subjects per cohort will be randomized to receive SPR720
Drug: SPR720 for SAD
Placebo comparator
Placebo for SAD
2 out of 8 subjects per cohort will be randomized to receive placebo
Drug: Placebo for SAD
Experimental
SPR720 for MAD
6 out of 8 subjects per cohort will be randomized to receive SPR720
Drug: SPR720 for MAD
Placebo comparator
Placebo for MAD
2 out of 8 subjects per cohort will be randomized to receive placebo
Drug: Placebo for MAD

Interventions

DrugSPR720 for SAD
Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
Also known as: SPR720 Oral Capsule
DrugPlacebo for SAD
Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
Also known as: Placebo oral Capsule
DrugSPR720 for MAD
Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
Also known as: SPR720 Oral Capsule
DrugPlacebo for MAD
Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
Also known as: Placebo Oral Capsule

What researchers measure

Primary outcomes

Treatment emergent adverse events assessments after single and multiple dose administration at baseline and repeatedly until study completion [Safety and Tolerability]
Incidence and severity of AEs
Time frame: Day 1 through last follow-up visit (5-7 days after last dose)

Secondary outcomes

Assessment of Pharmacokinetic Parameter (plasma): Cmax measurement
Maximum concentration of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): CmaxSS measurement
Maximum concentration of study drug in plasma at steady state
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): CminSS
Lowest concentration of study drug in a dosing interval in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): Ctrough
Concentration of study drug at the end of the dosing interval in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): CavSS
Average concentration of study drug in plasma during a dosing interval
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): Tmax
The time to maximum observed concentration of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): kel
Elimination rate constant of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): t1/2
Terminal elimination half-life of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): AUC0-24
Area under the concentration-time curve (AUC) of study drug in plasma from 0 to 24 hours post dose (dose escalation)
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): AUC0-tau
Area under the concentration-time curve (AUC) from 0 to tau, where tau is the dosing interval (multiple dose only) of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Parameter (plasma): AUC0-t
Area under the concentration-time curve (AUC) of study drug in plasma from the time of dosing to the time of the last measurable concentration
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): AUC0-inf
AUC extrapolated to infinity of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Parameter (plasma): AUC%extrapolated
Residual area of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): Degree of fluctuation
(Cmax-Cmin)/Cavss of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (plasma): Swing
(Cmaxss-Cminss)/Cminss of study drug in plasma
Time frame: From Day 1 pre-dose to 48 hours post last dose
Assessment of Pharmacokinetic Parameter (urine): SPR719
amount of SPR719 excreted in urine
Time frame: From Day 1 pre-dose to 24 hours post last dose

Study locations

1 site

Simbec Research, Ltd.
Merthyr Tydfil,, Mid Glamorgan CF48 4DR, United Kingdom

References and documents

Publications

Talley AK, Thurston A, Moore G, Gupta VK, Satterfield M, Manyak E, Stokes S, Dane A, Melnick D. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0120821. doi: 10.1128/AAC.01208-21. Epub 2021 Sep 7. PubMed 34491803 ↗

Individual participant data

Plan to share: No

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Oct 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03796910
Lead sponsor: Spero Therapeutics
Collaborators: Simbec Research
Responsible party: Sponsor
First posted: Jan 8, 2019
Start date: Dec 18, 2018
Primary completion: Sep 24, 2019
Completion: Sep 24, 2019
Last update: Oct 28, 2019

Study contacts

Annelize Koch, MBChB

principal investigator · Simbec Research

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Spero Therapeutics

Start the discussion